Virological and immunological effects of salvage therapy following treatment interruption and a shift in HIV-1 resistance genotype

Journal of Medical Virology

Volumn 68, Issue 3, 2002, Pages 305-310

  Izopet, Jacques ^a   Souyris, Corinne ^a   Sandres Sauné, Karine ^a   Puissant, Bénédicte ^a   Obadia, Martine ^a   Pasquier, Christophe ^a   Puel, Jacqueline ^a   Blancher, Antoine ^a   Massip, Patrice ^a  

^a CHU PURPAN   (France)

Author keywords

CD4+; CD8+; Lymphocyte count; Salvage antiretroviral therapy; Treatment interruption

Indexed keywords

ABACAVIR; ADEFOVIR; CD4 ANTIGEN; CD8 ANTIGEN; EFAVIRENZ; INDINAVIR; LAMIVUDINE; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; ZIDOVUDINE;

ADULT; ANTIVIRAL ACTIVITY; ARTICLE; CLINICAL ARTICLE; CROSS RESISTANCE; DRUG EFFECT; ENZYME INHIBITION; FEMALE; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY; LYMPHOCYTE COUNT; MALE; SALVAGE THERAPY; T LYMPHOCYTE ACTIVATION; VIROLOGY; VIRUS RESISTANCE;

ADULT; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; CD8-POSITIVE T-LYMPHOCYTES; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; LYMPHOCYTE COUNT; MALE; MIDDLE AGED; REVERSE TRANSCRIPTASE INHIBITORS; RNA, VIRAL; SALVAGE THERAPY;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 0036836630     PISSN: 01466615     EISSN: None     Source Type: Journal    
DOI: 10.1002/jmv.10204     Document Type: Article

References (13)

1. Deeks SG, Wrin T, Liegler T, Hoh R, Hayden M, Barbour JD, Hellmann NS, Petropoulos CJ, McCune JM, Hellerstein MK, Grant RM. 2001. Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia. N Engl J Med 344:472-480.
2. Devereux HL, Youle M, Johnson MA, Loveday C. 1999. Rapid decline in detectability of HIV-1 drug resistance mutations after stopping therapy. AIDS 13:F123-127.
3. Hance AJ, Lemiale V, Izopet J, Lecossier D, Joly V, Massip P, Mammano F, Descamps D, Brun-Vezinet F, Clavel F. 2001. Changes in human immunodeficiency virus type 1 populations after treatment interruption in patients failing antiretroviral therapy. J Virol 75:6410-6417.
4. Hirsch MS, Brun-Vezinet F, D'Aquila RT, Hammer SM, Johnson VA, Kuritzkes DR, Loveday C, Mellors JW, Clotet B, Conway B, Demeter LM, Vella S, Jacobsen DM, Richman DD. 2000. Antiretroviral drug resistance testing in adult HIV-1 infection: recommendations of an International AIDS Society-USA Panel. Jama 283:2417-2426.
5. Izopet I, Massip P, Souyris C, Sandres K, Puissant B, Obadia M, Pasquier C, Bonnet E, Marchou B, Puel J. 2000. Shift in HIV resistance genotype after treatment interruption and short-term antiviral effect following a new salvage regimen. AIDS 14:2247-2255.
6. Kaufmann D, Pantaleo G, Sudre P, Telenti A. 1998. CD4-cell count in HIV-1-infected individuals remaining viraemic with highly active antiretroviral therapy (HAART). Swiss HIV Cohort Study. Lancet 351:723-724.
7. Korber BT, Learn G, Mullins JI, Hahn BH, Wolinsky S. 1995. Protecting HIV databases. Nature 378:242-244.
8. Kwok S, Higuchi R. 1989. Avoiding false positives with PCR. Nature 339:237-238.
9. Levitz SM. 1998. Improvement in CD4+ cell counts despite persistently detectable HIV load. N Engl J Med 338:1074-1075.
10. Miller V, Sabin C, Hertogs K, Bloor S, Martinez-Picado J, D'Aquila R, Larder B, Lutz T, Gute P, Weidmann E, Rabenau H, Phillips A, Staszewski S. 2000. Virological and immunological effects of treatment interruptions in HIV-1 infected patients with treatment failure. AIDS 14:2857-2867.
11. Saitou N, Nei M. 1987. The neighbor-joining method: a new method for reconstructing phylogenetic trees. Mol Biol Evol 4: 406-425.
12. Verhofstede C, Wanzeele FV, Van Der Gucht B, De Cabooter N, Plum J. 1999. Interruption of reverse transcriptase inhibitors or a switch from reverse transcriptase to protease inhibitors resulted in a fast reappearance of virus strains with a reverse transcriptase inhibitor-sensitive genotype. AIDS 13:2541-2546.
13. Wood E, Yip B, Hogg RS, Sherlock CH, Jahnke N, Harrigan RP, O'Shaughnessy MV, Montaner JS. 2000. Full suppression of viral load is needed to achieve an optimal CD4 cell count response among patients on triple drug antiretroviral therapy. AIDS 14:1955-1960.